Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
analgesic
antitussive opioid medication |
| gptkbp:activeIngredient |
gptkb:codeine
|
| gptkbp:affiliatedWith |
opioids
phenanthrenes |
| gptkbp:ATCCode |
R05DA04
|
| gptkbp:brand |
Codeine Contin
Codeine Phosphate Tablets |
| gptkbp:CASNumber |
41444-62-6
|
| gptkbp:cause |
tolerance
vomiting dizziness itching allergic reaction hypotension euphoria urinary retention dependence miosis dysphoria |
| gptkbp:chemicalFormula |
C18H24NO7P
|
| gptkbp:contraindication |
asthma
respiratory depression children under 12 |
| gptkbp:controlledSubstanceSchedule |
Schedule III (US, in combination)
Schedule II (US, when alone) |
| gptkbp:discoveredBy |
gptkb:Pierre_Jean_Robiquet
|
| gptkbp:discoveredIn |
1832
|
| gptkbp:eliminationHalfLife |
2.5–4 hours
|
| gptkbp:excretion |
urine
|
| https://www.w3.org/2000/01/rdf-schema#label |
codeine phosphate
|
| gptkbp:interactsWith |
gptkb:beer
CYP2D6 inhibitors other CNS depressants |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:PubChem_CID |
gptkb:DB00318
5284371 |
| gptkbp:riskFactor |
addiction
overdose |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
constipation drowsiness respiratory depression |
| gptkbp:UNII |
8L70Q75FXE
|
| gptkbp:usedFor |
pain relief
cough suppression |
| gptkbp:bfsParent |
gptkb:Co-codaprin
gptkb:Nurofen_Plus |
| gptkbp:bfsLayer |
7
|